Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
Status:
Terminated
Trial end date:
2019-05-06
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate whether selonsertib (SEL; GS-4997) can
cause fibrosis regression and reduce associated complications in adults with cirrhosis due to
NASH.